[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354909-105":59,"doc-detail-354909-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mutant-calreticulin-enables-potent-and-selective-car-t-cell-therapy-in-preclinical-models-of-myeloproliferative-neoplasms","Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms","","Adoptive transfer of engineered CAR-T cells shows efficacy in hematologic cancers, but BCR::ABL1-negative myeloproliferative neoplasms (MPNs) often lack effective options. This study targets mutant calreticulin (mCALR), a neoantigen absent in healthy tissues, by designing five mCALR-specific CARs. The lead construct was selected by in vitro cytotoxicity and then tested across cell lines, patient-derived samples, and orthotopic xenografts, measuring tumor burden, CAR-T infiltration, and survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mutant-calreticulin-enables-potent-and-selective-car-t-cell-therapy-in-preclinical-models-of-myeloproliferative-neoplasms/354909/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mutant-calreticulin-enables-potent-and-selective-car-t-cell-therapy-in-preclinical-models-of-myeloproliferative-neoplasms/354909.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-17","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What disease and target does the study focus on?","Question",{"text":112,"@type":113},"The study focuses on BCR::ABL1-negative myeloproliferative neoplasms and targets mutant calreticulin (mCALR) as a neoantigen.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the CAR-T constructs developed and selected?",{"text":117,"@type":113},"Five mCALR-directed CARs were designed from available monoclonal antibody sequences, and the best construct was chosen using functional in vitro assays against mCALR-positive cell lines.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports the CAR-T approach in this work?",{"text":121,"@type":113},"The lead CAR-T showed selective cytotoxicity, eliminated patient-derived MPN cells, controlled disease in xenograft models, and revealed potential resistance mechanisms through transcriptomic analyses.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354909,1790167626,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","Open access Original research  \nTo cite: Pesini C, Gil-Bellido M, S Millan L, et al. Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms. Journal for ImmunoTherapy of Cancer 2026;14:e012706 . doi:10.1136/jitc-2025-012706  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-012706](jitc-2025-012706)) .  \nJP and AR-L are joint senior authors.  \nAccepted 25 November 2025  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Ariel Ramirez-Labrada; [aramirezlabrada@yahoo.es](aramirezlabrada@yahoo.es)  \nDr Julian Pardo; [pardojim@unizar.es](pardojim@unizar.es)  \nMutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms  \nCecilia Pesini,1,2,3,4 Mario Gil-Bellido,1,5 Lorena S Millan,1 Carmen Oñate,1,3,4 Adanays Calvo-Pérez,1,3,5 Llipsy Santiago,1,2,6 Eldris Iglesias,7 Jorge Paúl Bernal,1,5 Miguel Araujo-Voces,5 Laura Paz Artigas,8 Laura García-Martínez,7  \nFrancisco J Roig,7,9 Nieves Movilla Meno,8 José Manuel Garcia-Aznar  ,8,10 Bárbara Menéndez-Jandula,11 María Teresa Olave,3,4,12,13  \nGemma Azaceta Reinares,3,4,13 Marta Garrote,14,15,16 Alberto Alvarez-Larrán,14,15 Eva M Gálvez,2,3,17 Diego Sánchez Martínez,3,4,5,18 Maykel A Arias,1,2,5  \nJulian Pardo  ,1,2,3,4,5 Ariel Ramirez-Labrada  1,2,3,4  \nABSTRACT  \nBackground The adoptive transfer of T cells engineered to express chimeric antigen receptors (CAR-T) has shown high efficacy and safety in treating various hematologic malignancies. However, many hematologic disorders, such as BCR::ABL1-negative myeloproliferative neoplasms (MPNs), lack effective treatment options. Some of these neoplasms are marked by a recurrent mutation that results in the expression of mutant calreticulin (mCALR), a neoantigen absent in healthy tissues, making it a highly specific and appealing target for CAR-T cell therapy. Methods Five distinct CARs were designed based on available monoclonal antibody sequences that target mCALR and were subsequently used to generate CAR-T cells. The most effective construct was selected through functional in vitro assays against mCALRpositive cell lines. Its efficacy was then evaluated in cell lines, patient-derived cells, and orthotopic xenograft models, assessing tumor burden, CAR-T cell infiltration, and animal survival. Bulk and single-cell RNA sequencing were performed on patient-derived cells and residual tumor cells from CART-treated mice, respectively, to investigate potential resistance mechanisms. The impact of the most relevant pathway alteration on CAR-T efficacy was also analyzed. Pharmacological rescue assays using targeted agents were then conducted.  \nResults Among the five constructs, one demonstrated superior and specific cytotoxicity against mCALRexpressing cells, with no activity against mCALRnegative controls. This CAR-T cell also eliminated patient-derived MPN cells and controlled disease progression in xenograft models, which correlated with the persistence of CAR-T cells and tumor infiltration. Transcriptomic profiling of patient samples and residual tumor cells in spleens of treated mice revealed upregulation of anti-apoptotic proteins. Functional assays confirmed reduced CAR-T efficacy in Bcl-2 high cells, which was restored by co-treatment with  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ CALR mutations generate a mutant-specific neoepitope (mCALR) restricted to malignant cells in BCR::ABL1 negative myeloproliferative neoplasms (MPNs) . Despite its potential as a therapeutic target, chimeric antigen receptor (CAR)-based immunotherapeutic strategies to exploit this neoepitope have not yet been successfully de","cbCaioPZ7scC6kRG","https://ap.wps.com/l/cbCaioPZ7scC6kRG","pdf",7969404,17,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"What disease and target does the study focus on?\",\"answer\":\"The study focuses on BCR::ABL1-negative myeloproliferative neoplasms and targets mutant calreticulin (mCALR) as a neoantigen.\"},{\"question\":\"How were the CAR-T constructs developed and selected?\",\"answer\":\"Five mCALR-directed CARs were designed from available monoclonal antibody sequences, and the best construct was chosen using functional in vitro assays against mCALR-positive cell lines.\"},{\"question\":\"What evidence supports the CAR-T approach in this work?\",\"answer\":\"The lead CAR-T showed selective cytotoxicity, eliminated patient-derived MPN cells, controlled disease in xenograft models, and revealed potential resistance mechanisms through transcriptomic analyses.\"}]","Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms | PDF",1790114770,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c104767d7f6d43297690309bf9becf09.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d23660becc2fcb736c963080bc90fa44.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25562d5d3a49e099056c3a5e6fd2c027.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd79add8cd532510dea85e8826118de8.webp",980,1306]